Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Relationship between the Induced Iron Overload Model and Hepatic Erythropoiesis in Xenopus laevis.

Sato K, Taniai M, Kato K, Kato T.

Zoolog Sci. 2020 Feb;37(1):61-69. doi: 10.2108/zs190102.

PMID:
32068375
2.

Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.

Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K.

J Gastroenterol Hepatol. 2020 Jan 23. doi: 10.1111/jgh.14989. [Epub ahead of print]

PMID:
31975453
3.

Transition in the etiology of liver cirrhosis in Japan: a nationwide survey.

Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y, Taniai M, Ishikawa T, Yasui K, Takaki A, Takaguchi K, Ido A, Kurosaki M, Kanto T, Nishiguchi S; Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH.

J Gastroenterol. 2020 Mar;55(3):353-362. doi: 10.1007/s00535-019-01645-y. Epub 2019 Nov 25.

PMID:
31768801
4.

A Case of Atypical Sarcoidosis Diagnosed by Massive Splenomegaly.

Saito S, Kodama K, Kogiso T, Yamanashi Y, Taniai M, Ariizumi S, Yamamoto M, Tokushige K.

Intern Med. 2019 Oct 31. doi: 10.2169/internalmedicine.3646-19. [Epub ahead of print]

5.

The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.

Tobari M, Hashimoto E, Taniai M, Kodama K, Kogiso T, Tokushige K, Yamamoto M, Takayoshi N, Satoshi K, Tatsuo A.

J Gastroenterol Hepatol. 2019 Oct 9. doi: 10.1111/jgh.14867. [Epub ahead of print]

PMID:
31597206
6.

A case of Fontan-related hepatocellular carcinoma successfully treated with proton beam therapy.

Ogasawara Y, Kogiso T, Sagawa T, Kodama K, Taniai M, Numajiri H, Sakurai H, Tokushige K.

Clin J Gastroenterol. 2020 Feb;13(1):73-78. doi: 10.1007/s12328-019-01010-9. Epub 2019 Jul 4.

PMID:
31273674
7.

Characteristics of acute hepatitis A virus infection before and after 2001: A hospital-based study in Tokyo, Japan.

Kogiso T, Sagawa T, Oda M, Yoshiko S, Kodama K, Taniai M, Tokushige K.

J Gastroenterol Hepatol. 2019 Oct;34(10):1836-1842. doi: 10.1111/jgh.14655. Epub 2019 Apr 10.

PMID:
30861194
8.

Hepatocellular carcinoma after direct-acting antiviral drug treatment in patients with hepatitis C virus.

Kogiso T, Sagawa T, Kodama K, Taniai M, Katagiri S, Egawa H, Yamamoto M, Tokushige K.

JGH Open. 2018 Nov 9;3(1):52-60. doi: 10.1002/jgh3.12105. eCollection 2019 Feb.

9.

Differences in the genetic backgrounds of patients with alcoholic liver disease and non-alcoholic fatty liver disease.

Yamamoto K, Kogiso T, Taniai M, Hashimoto E, Tokushige K.

JGH Open. 2018 Oct 17;3(1):17-24. doi: 10.1002/jgh3.12097. eCollection 2019 Feb.

10.

POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33.

Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, Aiba Y, Nakamura H, Kouno H, Kouno H, Ohta H, Sugi K, Nikami T, Yamashita T, Katsushima S, Komeda T, Ario K, Naganuma A, Shimada M, Hirashima N, Yoshizawa K, Makita F, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Yamashita H, Matsushita K, Tsunematsu S, Yabuuchi I, Nishimura H, Shimada Y, Yamauchi K, Komatsu T, Sugimoto R, Sakai H, Mita E, Koda M, Nakamura Y, Kamitsukasa H, Sato T, Nakamuta M, Masaki N, Takikawa H, Tanaka A, Ohira H, Zeniya M, Abe M, Kaneko S, Honda M, Arai K, Arinaga-Hino T, Hashimoto E, Taniai M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Takaki A, Yamagiwa S, Seike M, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Ebinuma H, Himoto T, Murata K, Shimoda S, Nagaoka S, Abiru S, Komori A, Migita K, Ito M, Yatsuhashi H, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M.

Sci Rep. 2019 Jan 14;9(1):102. doi: 10.1038/s41598-018-36490-1.

11.

Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign.

Tobari M, Hashimoto E, Taniai M, Ikarashi Y, Kodama K, Kogiso T, Tokushige K, Takayoshi N, Hashimoto N.

J Gastroenterol Hepatol. 2019 Aug;34(8):1404-1410. doi: 10.1111/jgh.14585. Epub 2019 Jan 15.

PMID:
30590868
12.

Impact of continued administration of tolvaptan on cirrhotic patients with ascites.

Kogiso T, Sagawa T, Kodama K, Taniai M, Tokushige K.

BMC Pharmacol Toxicol. 2018 Dec 18;19(1):87. doi: 10.1186/s40360-018-0277-3.

13.

An intensive medical care network led to successful living-donor liver transplantation in late-onset hepatic failure with disseminated Staphylococcus aureus infection.

Kure R, Uehara N, Inoue K, Kogiso T, Kodama K, Taniai M, Tokushige K, Nakano M, Egawa H, Yamamoto M.

Clin J Gastroenterol. 2019 Apr;12(2):112-119. doi: 10.1007/s12328-018-0904-y. Epub 2018 Sep 14.

PMID:
30218430
14.

Clinicopathological investigation of steatohepatitic hepatocellular carcinoma: A multicenter study using immunohistochemical analysis of adenoma-related markers.

Taniai M, Hashimoto E, Tobari M, Kodama K, Tokushige K, Yamamoto M, Takayama T, Sugitani M, Sano K, Kondo F, Fukusato T.

Hepatol Res. 2018 Nov;48(12):947-955. doi: 10.1111/hepr.13203. Epub 2018 Oct 15.

PMID:
30058778
15.

Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study.

Kogiso T, Egawa H, Teramukai S, Taniai M, Hashimoto E, Tokushige K, Sakisaka S, Sakabayashi S, Yamamoto M, Umeshita K, Uemoto S.

Hepatol Commun. 2017 May 16;1(5):394-405. doi: 10.1002/hep4.1037. eCollection 2017 Jul.

16.

The Clinical Difference in the Platelet Counts between Liver Cirrhosis with Nonalcoholic Fatty Liver Disease and Hepatitis C Virus.

Ikarashi Y, Kodama K, Taniai M, Hashimoto E, Tokushige K.

Intern Med. 2018 Apr 15;57(8):1065-1070. doi: 10.2169/internalmedicine.9853-17. Epub 2017 Dec 21.

17.

The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.

Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K.

Intern Med. 2017 Nov 15;56(22):2993-3001. doi: 10.2169/internalmedicine.9033-17. Epub 2017 Sep 25.

18.

Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population.

Kawashima M, Hitomi Y, Aiba Y, Nishida N, Kojima K, Kawai Y, Nakamura H, Tanaka A, Zeniya M, Hashimoto E, Ohira H, Yamamoto K, Abe M, Nakao K, Yamagiwa S, Kaneko S, Honda M, Umemura T, Ichida T, Seike M, Sakisaka S, Harada M, Yokosuka O, Ueno Y, Senju M, Kanda T, Shibata H, Himoto T, Murata K, Miyake Y, Ebinuma H, Taniai M, Joshita S, Nikami T, Ota H, Kouno H, Kouno H, Nakamuta M, Fukushima N, Kohjima M, Komatsu T, Komeda T, Ohara Y, Muro T, Yamashita T, Yoshizawa K, Nakamura Y, Shimada M, Hirashima N, Sugi K, Ario K, Takesaki E, Naganuma A, Mano H, Yamashita H, Matsushita K, Yamauchi K, Makita F, Nishimura H, Furuta K, Takahashi N, Kikuchi M, Masaki N, Tanaka T, Tamura S, Mori A, Yagi S, Shirabe K, Komori A, Migita K, Ito M, Nagaoka S, Abiru S, Yatsuhashi H, Yasunami M, Shimoda S, Harada K, Egawa H, Maehara Y, Uemoto S, Kokudo N, Takikawa H, Ishibashi H, Chayama K, Mizokami M, Nagasaki M, Tokunaga K, Nakamura M.

Hum Mol Genet. 2017 Feb 1;26(3):650-659. doi: 10.1093/hmg/ddw406.

PMID:
28062665
19.

A case of gastrojejunocolic fistula with steatohepatitis.

Omori T, Tokushige K, Kinoshita F, Ito A, Taniai M, Taneichi M, Iizuka B, Itabashi M, Nagashima Y, Yamamoto M, Nakamura S, Hashimoto E.

Clin J Gastroenterol. 2017 Feb;10(1):23-31. doi: 10.1007/s12328-016-0703-2. Epub 2016 Dec 19.

PMID:
27995467
20.

Successful Treatment of Ascites using a Denver® Peritoneovenous Shunt in a Patient with Paroxysmal Nocturnal Hemoglobinuria and Budd-Chiari syndrome.

Kogiso T, Hashimoto E, Ito T, Hara T, Ikarashi Y, Kodama K, Taniai M, Torii N, Yoshinaga K, Morita S, Takahashi Y, Tanaka J, Sakai S, Yamamoto M, Tokushige K.

Intern Med. 2016;55(20):2957-2963. Epub 2016 Oct 15.

21.

Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites.

Kogiso T, Yamamoto K, Kobayashi M, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K.

Hepatol Res. 2017 Aug;47(9):835-844. doi: 10.1111/hepr.12822. Epub 2016 Nov 15.

PMID:
27670393
22.

Four cases of type 1 diabetes mellitus showing sharp serum transaminase increases and hepatomegaly due to glycogenic hepatopathy.

Ikarashi Y, Kogiso T, Hashimoto E, Yamamoto K, Kodama K, Taniai M, Torii N, Takaike H, Uchigata Y, Tokushige K.

Hepatol Res. 2017 Mar;47(3):E201-E209. doi: 10.1111/hepr.12713. Epub 2016 Apr 24.

PMID:
27027269
23.

[The process of development on analysis and diagnosis of hepatitis viruses].

Okuno N, Taniai M, Hashimoto E.

Nihon Rinsho. 2015 Dec;73 Suppl 9:18-21. Japanese. No abstract available.

PMID:
26845900
24.

Recurrent cutaneous eosinophilic vasculitis.

Sawada C, Taniai M, Kawashima M, Ishiguro N.

Eur J Dermatol. 2016 Jan-Feb;26(1):108-9. doi: 10.1684/ejd.2015.2680. No abstract available.

PMID:
26678510
25.

Cholesteryl Pullulan Encapsulated TNF-α Nanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza Virus.

Nagatomo D, Taniai M, Ariyasu H, Taniguchi M, Aga M, Ariyasu T, Ohta T, Fukuda S.

Biomed Res Int. 2015;2015:471468. doi: 10.1155/2015/471468. Epub 2015 Sep 1.

26.

Spontaneous clearance of HCV accompanying hepatitis after liver transplantation.

Kogiso T, Hashimoto E, Ikarashi Y, Kodama K, Taniai M, Torii N, Egawa H, Yamamoto M, Tokushige K.

Clin J Gastroenterol. 2015 Oct;8(5):323-9. doi: 10.1007/s12328-015-0602-y. Epub 2015 Sep 5.

PMID:
26342292
27.

Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis.

Kogiso T, Tokushige K, Hashimoto E, Ikarashi Y, Kodama K, Taniai M, Torii N, Shiratori K.

Hepatol Res. 2016 Mar;46(3):E194-200. doi: 10.1111/hepr.12547. Epub 2015 Jul 23.

PMID:
26123753
28.

Mycophenolate mofetil may induce prolonged severe anemia during pegylated-interferon/ribavirin/simeprevir therapy in liver transplant recipients.

Kogiso T, Tokushige K, Hashimoto E, Taniai M, Omori A, Kotera Y, Egawa H, Yamamoto M, Shiratori K.

Clin J Gastroenterol. 2015 Jun;8(3):156-61. doi: 10.1007/s12328-015-0570-2. Epub 2015 May 12.

PMID:
25963122
29.

Primary hyperoxaluria complicated with liver cirrhosis: A case report.

Kogiso T, Tokushige K, Hashimoto E, Miyakata C, Taniai M, Torii N, Omori A, Kotera Y, Egawa H, Yamamoto M, Nagata M, Shiratori K.

Hepatol Res. 2015 Dec;45(12):1251-5. doi: 10.1111/hepr.12494. Epub 2015 Mar 3.

PMID:
25594663
30.

Questionnaire survey on lifestyle of patients with nonalcoholic steatohepatitis.

Noto H, Tokushige K, Hashimoto E, Taniai M, Shiratori K.

J Clin Biochem Nutr. 2014 Nov;55(3):191-5. doi: 10.3164/jcbn.14-26. Epub 2014 Oct 21.

31.

Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis.

Nakamura M, Kondo H, Tanaka A, Komori A, Ito M, Yamamoto K, Ohira H, Zeniya M, Hashimoto E, Honda M, Kaneko S, Ueno Y, Kikuchi K, Shimoda S, Harada K, Arai K, Miyake Y, Abe M, Taniai M, Saibara T, Sakisaka S, Takikawa H, Onji M, Tsubouchi H, Nakanuma Y, Ishibashi H.

Hepatol Res. 2015 Aug;45(8):846-55. doi: 10.1111/hepr.12423. Epub 2014 Dec 11.

PMID:
25220608
32.

Investigation of ornithine carbamoyltransferase as a biomarker of liver cirrhosis.

Matsushita N, Hashimoto E, Tokushige K, Kodama K, Tobari M, Kogiso T, Torii N, Taniai M, Shiratori K, Murayama H.

Intern Med. 2014;53(12):1249-57. Epub 2014 Jun 15.

33.

Hepatocellular carcinoma based on cryptogenic liver disease: The most common non-viral hepatocellular carcinoma in patients aged over 80 years.

Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S.

Hepatol Res. 2015 Apr;45(4):441-7. doi: 10.1111/hepr.12372. Epub 2014 Jul 7.

PMID:
24923363
34.

[Liver cancer: progress in diagnosis and treatments. Topics: I. Epidemiology of hepatocellular carcinoma].

Taniai M.

Nihon Naika Gakkai Zasshi. 2014 Jan 10;103(1):4-10. Japanese. No abstract available.

PMID:
24605484
35.

Characteristics and diagnosis of NAFLD/NASH.

Hashimoto E, Taniai M, Tokushige K.

J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:64-70. doi: 10.1111/jgh.12271. Review.

PMID:
24251707
36.

Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: Importance of corticosteroid therapy.

Yoshioka Y, Taniai M, Hashimoto E, Haruta I, Shiratori K.

Hepatol Res. 2014 Sep;44(9):947-55. doi: 10.1111/hepr.12210. Epub 2013 Aug 19.

PMID:
23879195
37.

Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease.

Tokushige K, Hashimoto E, Kodama K, Tobari M, Matsushita N, Kogiso T, Taniai M, Torii N, Shiratori K, Nishizaki Y, Ohga T, Ohashi Y, Sato T.

J Gastroenterol. 2013 Dec;48(12):1392-400. doi: 10.1007/s00535-013-0766-5. Epub 2013 Mar 13.

38.

Hepatic and extrahepatic malignancies in cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease.

Kodama K, Tokushige K, Hashimoto E, Taniai M, Shiratori K.

Alcohol Clin Exp Res. 2013 Jan;37 Suppl 1:E247-52. doi: 10.1111/j.1530-0277.2012.01900.x.

PMID:
23320802
39.

Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population.

Nakamura M, Nishida N, Kawashima M, Aiba Y, Tanaka A, Yasunami M, Nakamura H, Komori A, Nakamuta M, Zeniya M, Hashimoto E, Ohira H, Yamamoto K, Onji M, Kaneko S, Honda M, Yamagiwa S, Nakao K, Ichida T, Takikawa H, Seike M, Umemura T, Ueno Y, Sakisaka S, Kikuchi K, Ebinuma H, Yamashiki N, Tamura S, Sugawara Y, Mori A, Yagi S, Shirabe K, Taketomi A, Arai K, Monoe K, Ichikawa T, Taniai M, Miyake Y, Kumagi T, Abe M, Yoshizawa K, Joshita S, Shimoda S, Honda K, Takahashi H, Hirano K, Takeyama Y, Harada K, Migita K, Ito M, Yatsuhashi H, Fukushima N, Ota H, Komatsu T, Saoshiro T, Ishida J, Kouno H, Kouno H, Yagura M, Kobayashi M, Muro T, Masaki N, Hirata K, Watanabe Y, Nakamura Y, Shimada M, Hirashima N, Komeda T, Sugi K, Koga M, Ario K, Takesaki E, Maehara Y, Uemoto S, Kokudo N, Tsubouchi H, Mizokami M, Nakanuma Y, Tokunaga K, Ishibashi H.

Am J Hum Genet. 2012 Oct 5;91(4):721-8. doi: 10.1016/j.ajhg.2012.08.010. Epub 2012 Sep 20.

40.

Roles of gender, obesity, and lifestyle-related diseases in alcoholic liver disease: Obesity does not influence the severity of alcoholic liver disease.

Taniai M, Hashimoto E, Tokushige K, Kodama K, Kogiso T, Torii N, Shiratori K.

Hepatol Res. 2012 Apr;42(4):359-67. doi: 10.1111/j.1872-034X.2011.00935.x. Epub 2011 Dec 13.

PMID:
22150916
41.

Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey.

Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S.

J Gastroenterol. 2011 Oct;46(10):1230-7. doi: 10.1007/s00535-011-0431-9. Epub 2011 Jul 13.

PMID:
21748549
42.

[Antiliver-kidney microsomal antibody].

Taniai M, Hashimoto E.

Nihon Rinsho. 2010 Jun;68 Suppl 6:589-91. Japanese. No abstract available.

PMID:
20942137
43.

Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C.

Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Shiratori K.

J Gastroenterol. 2010 Sep;45(9):960-7. doi: 10.1007/s00535-010-0237-1. Epub 2010 Apr 8.

PMID:
20376504
44.

Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.

Nomura T, Abe Y, Kamada H, Shibata H, Kayamuro H, Inoue M, Kawara T, Arita S, Furuya T, Yamashita T, Nagano K, Yoshikawa T, Yoshioka Y, Mukai Y, Nakagawa S, Taniai M, Ohta T, Serada S, Naka T, Tsunoda S, Tsutsumi Y.

J Control Release. 2011 Jan 5;149(1):8-14. doi: 10.1016/j.jconrel.2009.12.015. Epub 2009 Dec 24.

PMID:
20036293
45.

The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF.

Shibata H, Yoshioka Y, Abe Y, Ohkawa A, Nomura T, Minowa K, Mukai Y, Nakagawa S, Taniai M, Ohta T, Kamada H, Tsunoda S, Tsutsumi Y.

Biomaterials. 2009 Dec;30(34):6638-47. doi: 10.1016/j.biomaterials.2009.08.041. Epub 2009 Sep 17.

PMID:
19765818
46.

Clinical significance of serum ornithine carbamoyltransferase in patients with non-alcoholic steatohepatitis.

Tokushige K, Hashimoto E, Noto H, Yatsuji S, Tobari M, Torii N, Taniai M, Shiratori K, Murayama H.

Hepatol Res. 2009 Sep;39(9):939-43. doi: 10.1111/j.1872-034X.2009.00530.x.

PMID:
19712272
47.

Novel protein engineering strategy for creating highly receptor-selective mutant TNFs.

Nomura T, Abe Y, Kamada H, Inoue M, Kawara T, Arita S, Furuya T, Yoshioka Y, Shibata H, Kayamuro H, Yamashita T, Nagano K, Yoshikawa T, Mukai Y, Nakagawa S, Taniai M, Ohta T, Tsunoda S, Tsutsumi Y.

Biochem Biophys Res Commun. 2009 Oct 30;388(4):667-71. doi: 10.1016/j.bbrc.2009.08.052. Epub 2009 Aug 13.

PMID:
19682974
48.

Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease.

Tokushige K, Hashimoto E, Noto H, Yatsuji S, Taniai M, Torii N, Shiratori K.

J Gastroenterol. 2009;44(9):976-82. doi: 10.1007/s00535-009-0085-z. Epub 2009 May 30.

PMID:
19484180
49.

Treatment of nonalcoholic steatohepatitis with colestimide.

Taniai M, Hashimoto E, Tobari M, Yatsuji S, Haruta I, Tokushige K, Shiratori K.

Hepatol Res. 2009 Jul;39(7):685-93. doi: 10.1111/j.1872-034X.2009.00507.x. Epub 2009 Apr 7.

PMID:
19473432
50.

Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonists.

Mukai Y, Nakamura T, Yoshioka Y, Shibata H, Abe Y, Nomura T, Taniai M, Ohta T, Nakagawa S, Tsunoda S, Kamada H, Yamagata Y, Tsutsumi Y.

J Biochem. 2009 Aug;146(2):167-72. doi: 10.1093/jb/mvp065. Epub 2009 Apr 22.

PMID:
19386778

Supplemental Content

Loading ...
Support Center